Veradermics to Highlight Phase 3 VDPHL01 at Jefferies June 3 and Goldman Sachs June 8 Conferences
MANE•Veradermics will present at Jefferies Global Healthcare Conference June 3 and Goldman Sachs Healthcare Conference June 8, with CEO Reid Waldman leading corporate presentations. Its lead asset VDPHL01, an extended-release oral minoxidil tablet in Phase 3 with patents through 2043, targets a $30 billion pattern hair loss market.
1. Upcoming Investor Conferences
Veradermics management will present at the Jefferies Global Healthcare Conference on June 3 in New York and at the Goldman Sachs 47th Global Healthcare Conference on June 8 in Miami. CEO Reid Waldman will lead both investor presentations, with CCO Mark Neumann joining on June 3, and live webcasts will be available on the company’s website for 30 days.
2. Lead Asset VDPHL01 Details
VDPHL01 is an extended-release oral minoxidil tablet in Phase 3 development for pattern hair loss in both women and men. The proprietary formulation delivers sustained minoxidil absorption while avoiding high peak concentrations, aiming to improve efficacy and safety over immediate-release oral minoxidil.
3. Market Potential and Patent Coverage
Pattern hair loss affects an estimated 80 million people in the United States and represents the largest aesthetics market projected to reach $30 billion by 2028. VDPHL01 is protected by a broad library of patents with the earliest expiring in 2043, positioning it for long-term market exclusivity if approved.
